Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset by Makoto Nishio, MD, PhD, Takashi Seto, MD, PhD, Martin Reck, PhD, Edward B. Garon, MD, Kazuto Nishio, MD, PhD, Kazuo Kasahara, MD, PhD, Kazumi Nishino, MD, PhD, Miyako Satouchi, MD, PhD, Kiyotaka Yoh, MD, Hidetoshi Hayashi, MD, PhD, Kazuko Sakai, PhD, Sotaro Enatsu, MD, PhD, Bente Frimodt-Møller, MSc, Tomoko Matsui, Sunoj Chacko Varughese, MSc, Michelle Carlsen, MS, Carla Visseren-Grul, MD, Kazuhiko Nakagawa, MD, PhD

Get full text

Red blood cell-tumor cell interactions promote tumor cell progression by Thais Pereira-Veiga, Celso Yáñez-Gómez, Aleksi Pekkarinen, Carmen Abuín, Christine Blechner, Miriam González-Conde, Christian Mess, Sabine Vidal-y-Sy, Ayham Moustafa, Bente Siebels, Ana B. Dávila-Ibáñez, Pablo Cabezas-Sainz, Maider Santos, Laura Sánchez, Joao Gorgulho, Julian Götze, Kira Meißner, Juan Cueva, Patricia Palacios, Alexandra Cortegoso, Teresa Curiel, Carmela Rodríguez, Marta Carmona, Luis León-Mateos, Alicia Abalo, Laura Muinelo-Romay, Sven Peine, Milena Schmidt, Nadine Heuer-Olewinski, Martin Reck, Mustafa Abdo, Katrin Lamszus, Alexander T. Bauer, Rafael López-López, Klaus Pantel, Sabine Windhorst, Harriet Wikman, Clotilde Costa

Get full text